A class action lawsuit has been filed against Unicycive Therapeutics and certain officers for allegedly making false and misleading statements about their third-party manufacturing vendor's compliance with FDA standards. The complaint claims Unicycive did not properly inspect or audit the vendor's facility, risking delays in regulatory approval for their drug oxylanthanum carbonate. Investors who bought Unicycive securities between December 29, 2025, and June 29, 2026, may join the lawsuit. Those affected have until November 2, 2026, to request lead plaintiff status, with legal representation offered on a contingency fee basis.
Apple is expected to unveil its first foldable iPhone, called the iPhone Ultra, at its September 9 event, more than five years after Samsung's first foldable phone. The device will feature a 5.5-inch cover display that unfolds to 7.8 inches, a dual-l...
Wintermute, a major algorithmic market maker, has accumulated over $3 million worth of PONS tokens, the governance token for the Robinhood Chain's leading meme-coin launchpad. The purchases were made incrementally on Uniswap using a time-weighted ave...
Bitcoin miners have stopped selling their mined coins after investing over $30 billion in AI and high-performance computing infrastructure. This strategic shift led to a 15% reduction in mining capacity as companies repurposed resources away from Bit...
Super Micro Computer's stock has gained 35% in 2026, outperforming the S&P 500 but lagging behind peers like Dell and Hewlett Packard Enterprise due to cash flow challenges. The company showed strong revenue growth and margin improvement in Q4 FY2026...
Microsoft's stock is close to its all-time high of $549.20, driven by strong revenue growth from Azure and AI partnerships. However, rising capital expenditures have slowed free cash flow growth, creating uncertainty about the stock's next move. Inve...
